Verification evidence is still being completed.
PDF / print export
PharmaSynth
Tartu, Estonia
- Verified lead
- Pirkko Irene Penttila-Hiltunen
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Management Board Member
- 2026 technical specialization
- PET and SPECT Precursors, Custom Synthesis, and Small-Scale API Production
- Review cycle
- May 2026
- Full address
- Teaduspargi 7, 50411 Tartu, Estonia
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Estonian e-Business Register record confirming the current public representation lead for PharmaSynth AS.
- Editorial note
- PharmaSynth is published as an Estonia manufacturing node because the official business register exposes a current board representative while the company site ties the Tartu operation to PET/SPECT precursor production and API-grade GMP pathways.
PET and SPECT Precursors, Custom Synthesis, and Small-Scale API Production
API manufacturer registration number 726 (AS-mf), GMP certificate listed via EudraGMDP, GMP-guideline production for PET and SPECT precursors
PharmaSynth is published as an Estonia manufacturing node because the official business register exposes a current board representative while the company site ties the Tartu operation to PET/SPECT precursor production and API-grade GMP pathways.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Tartu, Estonia
PharmaSynth
PET and SPECT Precursors, Custom Synthesis, and Small-Scale API Production · Specialty imaging-precursor and small-batch API platform
PharmaSynth runs pet and spect precursor supply, custom organic synthesis, and small-scale api production in Tartu, Estonia.
- Lead
- Pirkko Irene Penttila-Hiltunen (verified ↗)
- Address
- Teaduspargi 7, 50411 Tartu, Estonia (source ↗)
- Compliance
- GMP certificate listed via EudraGMDP · GMP-guideline production for PET and SPECT precursors
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Specialty imaging-precursor and small-batch API platform
- Capabilities
- PET and SPECT Precursor Supply · Custom Organic Synthesis · Small-Scale API Production
- Founded
- 2004
- Headcount
- 1-10
Clinical profileSTATUS: VERIFIED MARCH 2026
Pirkko Irene Penttila-Hiltunen
Management Board Member
Full addressTeaduspargi 7, 50411 Tartu, Estonia
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official PharmaSynth contact page listing the Tartu Science Park premises.
Open sourceSpecialty imaging-precursor and small-batch API platform
Tartu, Estonia. PET and SPECT Precursors, Custom Synthesis, and Small-Scale API Production. Review completed on 21 Mar 2026.
Estonian business-register oversight and EU GMP / EudraGMDP framework
API manufacturer registration number 726 (AS-mf), GMP certificate listed via EudraGMDP, GMP-guideline production for PET and SPECT precursors
PET and SPECT Precursors, Custom Synthesis, and Small-Scale API Production
PharmaSynth is published as an Estonia manufacturing node because the official business register exposes a current board representative while the company site ties the Tartu operation to PET/SPECT precursor production and API-grade GMP pathways.
Editorial note
PharmaSynth is published as an Estonia manufacturing node because the official business register exposes a current board representative while the company site ties the Tartu operation to PET/SPECT precursor production and API-grade GMP pathways.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
PET and SPECT Precursor Supply
Custom Organic Synthesis
Small-Scale API Production
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Precursor and standard synthesis workflows
Custom organic synthesis laboratories
Small-scale API production capability
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is PharmaSynth located?
- PharmaSynth operates from Teaduspargi 7, 50411 Tartu, Estonia, Tartu, Estonia.
- Who runs PharmaSynth?
- PharmaSynth is led by Pirkko Irene Penttila-Hiltunen, Management Board Member. Verified 21 Mar 2026.
- What certifications does PharmaSynth hold?
- PharmaSynth is documented under GMP certificate listed via EudraGMDP, GMP-guideline production for PET and SPECT precursors.
- What does PharmaSynth do?
- PharmaSynth runs pet and spect precursor supply, custom organic synthesis, and small-scale api production in Tartu, Estonia. Core capabilities: PET and SPECT Precursor Supply, Custom Organic Synthesis, Small-Scale API Production.
Editorial context
Related technical briefs
Briefs that name Tartu as a covered market or city.